Cadrenal Therapeutics (CVKD) said Tuesday it has signed a collaboration agreement with Abbott (ABT) to support a trial of its tecarfarin anticoagulation and hemocompatibility with left ventricular assist devices.
Financial terms were not disclosed.
Under the terms of the agreement, Abbott will support Cadrenal on the planning and execution of the trial to evaluate the efficacy and safety of tecarfarin in patients with left ventricular assist devices.
Abbott will also share insights from recent trials and will support Cadrenal with trial design, site identification, trial awareness, and expertise.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.